BioSpace News Archive

Y-mAbs Therapeutics, Inc. announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

COVID-19 vaccines have once again become a hot topic in the United States as President Joe Biden pushes on with vaccination mandates in a bid to manage concerns around the Omicron variant ahead of the winter flu season.

Ivantis Inc., developer of the novel Hydrus® Microstent, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery.

PharmaCyte Biotech, Inc. NASDAQ: PMCB), announced today the financial results for its second quarter ended October 31, 2021, and provided an overview of recent operational highlights (PharmaCyte’s Fiscal Year begins May 1 and ends April 30).

All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.

MDoloris Medical Systems, leader in the field of objective analgesia/nociception monitoring during anesthesia and in intensive care, and Mindray, a global leader in developing and providing advanced medical devices and solutions, announce today the CE Mark and upcoming launch of the Mdoloris ANI-MR module.

Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today unveiled its next-generation of innovations to enable unbiased spatial phenotyping at unprecedented speeds, setting a new standard in spatial biology.

Abivax SA announces that Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, will present at the J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 12:00-12:40 pm ET.

Alethiomics, a drug discovery company focused on developing targeted therapies to treat a family of blood cancers called myeloproliferative neoplasms, launched today, backed by £6m seed financing from Oxford Science Enterprises.

Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15.